Cantor Fitzgerald Comments on TVTX FY2025 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Travere Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal expects that the company will post earnings of ($1.13) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.93) per share.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, October 31st. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.01. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The firm had revenue of $62.90 million for the quarter, compared to the consensus estimate of $60.87 million. During the same period last year, the firm posted ($1.17) EPS. The company’s revenue was up 69.6% on a year-over-year basis.

A number of other research firms have also issued reports on TVTX. Barclays boosted their target price on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Canaccord Genuity Group decreased their price objective on shares of Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a research report on Monday, September 30th. Wedbush increased their price objective on Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. Wells Fargo & Company upgraded Travere Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $9.00 to $27.00 in a research report on Monday, October 21st. Finally, Scotiabank boosted their price target on Travere Therapeutics from $23.00 to $27.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Travere Therapeutics Price Performance

TVTX stock opened at $19.46 on Wednesday. Travere Therapeutics has a 12 month low of $5.12 and a 12 month high of $20.33. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -4.28 and a beta of 0.70. The company has a fifty day moving average price of $18.23 and a 200 day moving average price of $14.75. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of TVTX. Millennium Management LLC grew its position in Travere Therapeutics by 33.9% in the 2nd quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock valued at $24,244,000 after buying an additional 747,406 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in Travere Therapeutics by 203.0% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 615,000 shares of the company’s stock valued at $5,055,000 after purchasing an additional 412,000 shares in the last quarter. Emerald Advisers LLC increased its position in shares of Travere Therapeutics by 19.8% during the 3rd quarter. Emerald Advisers LLC now owns 1,960,659 shares of the company’s stock valued at $27,430,000 after purchasing an additional 323,513 shares during the period. Emerald Mutual Fund Advisers Trust raised its stake in shares of Travere Therapeutics by 26.0% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company’s stock worth $16,588,000 after buying an additional 244,444 shares in the last quarter. Finally, Walleye Capital LLC lifted its holdings in shares of Travere Therapeutics by 70.1% in the third quarter. Walleye Capital LLC now owns 488,453 shares of the company’s stock valued at $6,833,000 after buying an additional 201,282 shares during the period.

Insider Buying and Selling

In other news, insider Jula Inrig sold 2,066 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $19.10, for a total transaction of $39,460.60. Following the completion of the transaction, the insider now directly owns 59,883 shares in the company, valued at approximately $1,143,765.30. The trade was a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Sandra Calvin sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $17.22, for a total value of $258,300.00. Following the completion of the sale, the chief accounting officer now owns 54,927 shares in the company, valued at approximately $945,842.94. This represents a 21.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,596 shares of company stock worth $527,262 over the last quarter. 4.06% of the stock is owned by company insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.